(Q42979298)

English

Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR.

scientific article published on 9 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR. (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

L Restivo

1

1 reference

Europe PubMed Central

12 November 2017

R Zampino

2

1 reference

Europe PubMed Central

12 November 2017

B Guerrera

3

1 reference

Europe PubMed Central

12 November 2017

L Ruggiero

4

1 reference

Europe PubMed Central

12 November 2017

L E Adinolfi

5

1 reference

Europe PubMed Central

12 November 2017

publication date

9 November 2011

1 reference

Europe PubMed Central

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

12 November 2017

19

1 reference

Europe PubMed Central

12 November 2017

5

1 reference

Europe PubMed Central

12 November 2017

346-352

1 reference

Europe PubMed Central

12 November 2017

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Hepatic steatosis and insulin resistance: does etiology make a difference?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01555.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2011.01555.X

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42979298&oldid=1590544125"